Oral presentation provides first REGN2810 data in patients with advanced cutaneous squamous cell carcinoma (CSCC) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive...

Sanofi and Regeneron Pharmaceuticals, Inc. today announced positive preliminary results with investigational REGN2810, a checkpoint inhibitor targeting PD-1 (programmed death 1), in patients with...

The first International Style Conference was jointly held in Niccolo Chengdu by T China and Chengdu International Finance Square (Chengdu IFS), dedicated to explore Style Transformation in China...

Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with the immune checkpoint inhibitor YERVOY®...

Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...

Forge Therapeutics, Inc., (Forge), a biotechnology company discovering first-in-class antibiotics using a breakthrough drug discovery platform, presented the first efficacy data for an LpxC...

Boston Biomedical, Inc., an industry leader in the development of next-generation cancer therapeutics designed to inhibit cancer stemness pathways, will present phase 1b/2 clinical data evaluating...

Today, National Geographic announced a series of events throughout the week of June 4th to commemorate World Oceans Day and highlight the importance of protecting the world's oceans in conjunction...

Healthier Choices Management Corp. (OCT Pink: HCMC.OB), a holding company specializing in providing consumers with healthier alternatives to everyday lifestyle choices, today announced that it...

IRET (NYSE: IRET), a real estate investment trust focusing on the acquisition, development, redevelopment and management of multifamily communities located primarily in select growth markets...